Literature DB >> 2802568

Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.

M Y Khan1, M Dizon, F W Kiel.   

Abstract

The in vitro activities of three quinolones (ofloxacin, difloxacin, and ciprofloxacin) were compared with those of trimethoprim-sulfamethoxazole, streptomycin, tetracycline, and rifampin against 47 Brucella melitensis strains. Ofloxacin was the most active of the test antimicrobial agents. It inhibited 90% of B. melitensis strains at a concentration of 0.02 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2802568      PMCID： PMC172669          DOI： 10.1128/AAC.33.8.1409

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

4.  In vitro activity of ciprofloxacin against Brucella melitensis.

Authors:  M Gobernado; E Cantón; M Santos
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

6.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Difloxacin metabolism and pharmacokinetics in humans after single oral doses.

Authors:  G R Granneman; K M Snyder; V S Shu
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes.

Authors:  H Koga
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.

Authors:  J Bosch; J Liñares; M J López de Goicoechea; J Ariza; M C Cisnal; R Martin
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790
View more
  12 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Use of ciprofloxacin in the treatment of brucellosis.

Authors:  M Doğanay; B Aygen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 4.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  Human brucellosis in a nonendemic country: a report from Germany, 2002 and 2003.

Authors:  S Al Dahouk; K Nöckler; A Hensel; H Tomaso; H C Scholz; R M Hagen; H Neubauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

Review 7.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

8.  Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Authors:  M Akova; O Uzun; H E Akalin; M Hayran; S Unal; D Gür
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Effect of carbon dioxide on broth microdilution susceptibility testing of Brucella spp.

Authors:  David R Lonsway; Laura A Jevitt; James R Uhl; Franklin R Cockerill; Mary E Anderson; Maureen M Sullivan; Barun K De; Jonathan R Edwards; Jean B Patel
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.